<DOC>
	<DOCNO>NCT00956722</DOCNO>
	<brief_summary>This exploratory trial Bovine Colostrum powder decrease translocation gut-derived microbial product immune activation HCV infection . The study design single-arm , open-label , before-and exploratory trial 10 week Bovine Colostrum Powder ( BCP ) reduce translocation intestinal microbial product immune activation patient suffer chronic hepatitis C virus ( HCV ) infection . The study population include HCV-infected ( genotype 1 ) men woman , ≥ 18 year age , receive anti-viral therapy time enrollment least previous 3 month . Having fail previous anti-viral therapy ( non responder ) , HCV recurrence 72 week therapy , develop side effect mandate stop anti viral therapy , consider eligible initiation treatment , plasma HCV RNA level ≥ 1000 I.U .</brief_summary>
	<brief_title>Hyperimmune Bovine Colostrum - TRAVELAN™ Patients With Chronic Hepatitis C Virus Infection Not Responding Standard Therapy</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Virus Diseases</mesh_term>
	<criteria>Chronic HCV infection ( genotype 1 ) , document positive anti HCV titer , confirm positive HCV RNA . Non responder previous antiviral therapy , HCV recurrence 72 week therapy , previous antiviral therapy stop due side effect , candidate treatment interferon + ribavirin . No antiviral therapy least 3 month . HCV RNA ≥1,000 IU obtain within 30 day prior study entry . Not currently list liver transplantation Female study subject reproductive potential ( defined girl reach menarche woman postmenopausal least 24 consecutive month , i.e. , menses within precede 24 month , undergone sterilization procedure ( hysterectomy bilateral oophorectomy ) must negative serum urine pregnancy test perform within 48 hour initiate protocolspecified medication ( ) unless otherwise specify product labeling . All study subject must agree participate conception process ( e.g. , active attempt become pregnant impregnate , sperm donation , vitro fertilization ) . If participate sexual activity could lead pregnancy , study volunteer must agree two reliable method contraception use simultaneously receive protocolspecified medication 1 month stop medication . NOTE : Hormonalbased method alone sufficient . At least two follow method MUST use appropriately unless documentation menopause , sterilization , azoospermia present : Condoms ( male female ) without spermicidal agent . Condoms recommend appropriate use contraception method effective prevent HIV transmission ; Diaphragm cervical cap spermicide ; IUD ; Hormonalbased contraception . Study subject reproductive potential ( girl reach menarche woman postmenopausal least 24 consecutive month undergone hysterectomy and/or bilateral oophorectomy eligible without require use contraceptive . Written oral documentation communicate clinician clinician 's staff require one following : Physician report/letter ; Operative report source documentation patient record ( laboratory report azoospermia require document successful vasectomy ) ; Discharge summary ; Laboratory report azoospermia ; FSH measurement elevate menopausal range establish report laboratory . Men woman age &gt; 18 year . Ability willingness subject legal guardian/representative provide inform consent . Pregnancy BreastFeeding Continuous use follow medication 3 day within 30 day study entry : Immunosuppressives ; Immune modulators ; Systemic glucocorticoid ; Antineoplastic agent ; Active drug alcohol use dependence , opinion site investigator , would interfere adherence study requirement . Serious illness require systemic treatment and/or hospitalization within 30 day prior entry .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2011</verification_date>
</DOC>